Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.98 -1.10 (-2.00%)

Streaming Delayed Price Updated: 3:35 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

Where CRISPR Therapeutics Stands With Analysts ↗

August 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

July 29, 2022

This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment

Via MarketBeat

Will a Recession Cause a Housing Crash in 2022? ↗

July 27, 2022

For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.

Via InvestorPlace

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Analyst Ratings for CRISPR Therapeutics ↗

June 13, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗

July 15, 2022

Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗

July 15, 2022

The group has several commonalities, including strong ratings and promising charts.

Via Investor's Business Daily

6 Cathie Wood Stocks to Buy on the Dip ↗

July 14, 2022

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers.

Via InvestorPlace

Fed To Hike Interest Rates 100 Basis Points? What To Expect From Stocks ↗

July 14, 2022

The CPI report came in at 9.1% well above analyst expectations. Now there is a strong possibility of a 100 basis point rate hike at the next FOMC meeting.

Via Talk Markets

5 Best Stocks to Buy if You Have $100 to Spend ↗

July 10, 2022

My son became an investor this year, taking a job that pays more than his single, frugal lifestyle consumes. He asked me what stocks he might buy with

Via InvestorPlace

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them? ↗

July 07, 2022

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Via Investor's Business Daily

Jim Cramer Says This Company Isn't Making Money ↗

June 24, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added.

Via Benzinga

Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know ↗

June 23, 2022

Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics...

Via Benzinga

Why CRISPR Therapeutics Stock Is Falling ↗

June 22, 2022

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.

Via Benzinga

Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know ↗

June 22, 2022

Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗

June 22, 2022

Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.

Via Talk Markets

CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock ↗

June 16, 2022

On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr.

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases? ↗

June 13, 2022

Crispr and Vertex tested their gene-edited drug in two blood diseases.

Via Investor's Business Daily

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive ↗

June 13, 2022

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic...

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

June 11, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing ↗

June 10, 2022

The company is using a different approach to tackle the blood disease.

Via Investor's Business Daily

7 No-Brainer Biotech Stocks to Add to Your Buy List ↗

June 09, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

Via InvestorPlace

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.